San Francisco startup Structure Therapeutics is also focusing on an oral, at the time-each day GLP-1 drug called GSBR-1290—the drug surpassed Wall Road’s expectations in June any time a mid-phase study showed regular weight loss of about 6% and it options to begin An additional mid-phase demo in direction of the top of the calendar year—that